Chengdu Xinhengchuang Pharmaceutical

Chengdu Xinhengchuang Pharmaceutical is a China-based pharmaceutical company specializing in the research, development, and manufacturing of high-end chemical active pharmaceutical ingredients (APIs) and advanced intermediates. Founded in 2016 and located in the Chengdu Medical City, the company focuses on therapeutic areas such as antiviral, cardiovascular, and metabolic diseases. Their product portfolio includes key treatments for Hepatitis B, Type 2 diabetes, and heart failure, including generic versions of Entecavir and Empagliflozin. Xinhengchuang operates with a strong emphasis on quality management systems, providing CDMO services to global partners while advancing its own pipeline of finished dosage forms. The company is recognized for its technical expertise in complex chemical synthesis and its contribution to the global supply of essential pharmaceutical building blocks.